Appropriate Coverage of Specialty Drugs in Healthcare: Balancing Innovation, Access, and Affordability

May 2026

Specialty drugs represent some of the most significant advances in modern medicine. Offering life-changing or even life-saving treatments for complex, chronic, and rare conditions such as cancer, multiple sclerosis, rheumatoid arthritis, and genetic disorders. However, these medications also come with extraordinary costs, complex handling requirements, and growing utilization rates.

As healthcare systems, employers, and payers wrestle with how to cover these high-cost therapies, the question becomes: What does appropriate coverage of specialty drugs look like? This article explores how to define appropriate coverage and balance access with fiscal responsibility in a rapidly evolving pharmaceutical landscape.

What Are Specialty Drugs?

Specialty drugs are generally defined by several factors:

• • High cost (often over $1,000 per month or more per dose)
  • Complex administration (injectable, infused, or oral therapies requiring monitoring)
  • Special handling (temperature-sensitive, limited distribution)
  • Use for rare or serious conditions (e.g., autoimmune diseases, cancer, HIV, genetic disorders)

Examples include biologics like Humira, oncology therapies like Keytruda, and gene therapies like Zolgensma.

The Challenge of Specialty Drug Coverage

While specialty drugs account for less than 2% of prescriptions, they represent over 50% of total pharmacy spend in many employer and health plan settings. This outsized impact creates tension between:

• • Access for patients in need,
  • Affordability for payers and employers,
  • Sustainability for the healthcare system.

Principles of Appropriate Specialty Drug Coverage

1. Evidence-Based Access

Coverage should be driven by clinical evidence, not cost alone. This means:

• • Aligning coverage with FDA indications and clinical guidelines
  • Requiring peer-reviewed data for efficacy and safety
  • Covering drugs when there is a clear therapeutic benefit for the patient

This approach prevents inappropriate denials while avoiding overuse in off-label or low-value situations.

2. Prior Authorization for Appropriateness

Prior authorization (PA) is often necessary for specialty drugs to ensure:

• • Correct diagnosis
  • Step therapy has been followed (i.e., first trying lower-cost alternatives)
  • Dosage and duration align with best practices

When managed efficiently and transparently, PA helps control inappropriate utilization without unduly delaying care.

3. Use of Centers of Excellence

For ultra-complex therapies like gene therapy or CAR-T cell treatments, limiting coverage to certified centers of excellence ensures that patients receive expert care and monitoring while maintaining quality and safety standards.

4. Value-Based Contracts

Payers and pharmacy benefit managers (PBMs) are increasingly using outcomes-based or value-based arrangements, in which the manufacturer provides rebates or risk-sharing if the drug doesn’t deliver expected clinical outcomes.

This aligns coverage with real-world performance and helps mitigate financial risk.

5. Cost-Sharing Protections

Patients prescribed specialty drugs often face high out-of-pocket costs. Appropriate coverage should include:

• • Caps on patient cost-sharing
  • Access to copay assistance or manufacturer programs
  • Tiered formularies that don’t unfairly penalize those with rare diseases

Affordability must be addressed to ensure that access is meaningful.

6. Specialty Pharmacy Management

Using a specialty pharmacy network enables tighter control over dispensing, adherence support, and patient education. This can reduce waste, improve outcomes, and streamline logistics for both providers and patients.

Risks of Inappropriate Coverage

Overly generous or lax coverage can lead to:

• • Overutilization of high-cost therapies without proven benefit
  • Unsustainable cost growth for payers and plan sponsors
  • Reduced incentive for price competition or innovation in delivery

On the other hand, overly restrictive coverage can result in:

• • Delayed or denied access to life-saving treatment
  • Increased patient dissatisfaction and adverse health outcomes
  • Legal or regulatory scrutiny

Finding the right balance is critical.

A Collaborative Approach

Appropriate specialty drug coverage requires coordination among:

• • Physicians: for clinical appropriateness and diagnosis accuracy
  • Payers and PBMs: for utilization management and contract negotiation
  • Patients: to ensure understanding of benefits and costs
  • Manufacturers: to support affordability and real-world outcomes

Open communication, transparency, and data sharing are key to ensuring specialty medications are used effectively and efficiently.

As specialty drugs become more prominent in the treatment landscape, health plans and employers must adopt coverage strategies that balance innovation with sustainability. Appropriate coverage doesn’t mean approving every request, or denying care to save money. It means using evidence, value, and compassion to ensure the right patients receive the right drugs at the right time, for the right price. Make sure to check out our linkedin page for more information http://linkedin.com/company/crystal-clear-rx or reach out at https://crystalclearrx.com/contact-us/